Islet Sciences Inc (NASDAQ:ONCE) Big Money Sentiment Crashed in Q4 2017 to 1.43

May 16, 2018 - By Joseph Taylor

Spark Therapeutics, Inc. (NASDAQ:ONCE) Corporate Logo

Positions for Islet Sciences Inc (NASDAQ:ONCE)

In Q4 2017 Islet Sciences Inc (NASDAQ:ONCE) big money sentiment decreased to 1.43, according to SEC.gov filings. So its down -1.51, from 2017Q3’s 2.94. 96 active investment managers started new and increased equity positions, while 67 decreased and sold stakes in Islet Sciences Inc so the sentiment dropped. Funds own 35.76 million shares, up from 33.64 million shares in 2017Q3. Funds holding Islet Sciences Inc in top 10 changed to 0 from 1 for a decrease of 1. In total 41 funds closed positions, 26 reduced and 55 increased. Also 41 funds bought new Islet Sciences Inc stakes.

Most Islet Sciences Inc Shareholders

Great Point Partners Llc owns 410,900 shares in Islet Sciences Inc as of Q4 2017. As of Q4 2017, 615,000 shares of Islet Sciences Inc are owned by Rock Springs Capital Management Lp. Eventide Asset Management Llc reported 324,000 shares. Baker Bros. Advisors Lp revealed 1.38 million shares position in Islet Sciences Inc. The Israel-based fund Sphera Funds Management Ltd. holds 100,000 shares or 0.6% of their long stock exposure.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.The firm is valued at $2.92 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.Currently it has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

ONCE is hitting $78.015 during the last trading session, after increased 0.91%.Currently Spark Therapeutics, Inc. is uptrending after 21.52% change in last May 16, 2017. ONCE has 213,077 shares volume. ONCE outperformed the S&P500 by 9.97%.

Spark Therapeutics, Inc. (NASDAQ:ONCE)’s earnings report is awaited on August, 1., according to Zacks. Analysts predict $-0.41 EPS, which is $1.48 up or 78.31 % from 2017’s $-1.89 EPS. After $-1.25 EPS was revealed last quarter, analysts now see EPS growth of -67.20 % for Spark Therapeutics, Inc..

Winslow Evans & Crocker has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Goldman Sachs Group invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). 143,800 were accumulated by Numeric Invsts Ltd Liability. California State Teachers Retirement owns 43,567 shs or 0% of their US capital. Eventide Asset Mgmt Ltd Limited Liability Company has invested 0.87% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Lord Abbett & Com Ltd Company accumulated 296,892 shs or 0.04% of the stock. Baker Bros Limited Partnership, New York-based fund reported 1.38 million shs. Voya Investment Mgmt Limited Liability has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Victory Cap Mngmt owns 394 shs or 0% of their US capital. Fil has 0.01% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 87,218 shs. California-based Parallax Volatility Advisers Lp has invested 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Rhenman And Ptnrs Asset Management owns 70,200 shs or 0.49% of their US capital. Ny State Common Retirement Fund stated it has 0% of its capital in Spark Therapeutics, Inc. (NASDAQ:ONCE). 23,348 were reported by Rmb Management. Moreover, Altrinsic Limited Liability Company has 0.06% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE).

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

A total of 18 analysts rate Spark Therapeutics (NASDAQ:ONCE) as follows: 10 “Buy”, 7 “Hold” and 1 “Sell”. Тherefore 56% are bullish. (NASDAQ:ONCE) has 35 ratings reports on 16 May 2018 according to StockzIntelligence. On Monday, December 11 the firm earned “Buy” rating by Cantor Fitzgerald. On Wednesday, May 9 the firm has “Buy” rating given by Stifel Nicolaus. On Wednesday, February 14 the firm has “Hold” rating given by J.P. Morgan. In Wednesday, January 24 report BMO Capital Markets maintained it with “Buy” rating and $66.0 target. On Tuesday, May 1 JP Morgan maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) rating. JP Morgan has “Neutral” rating and $63 target. On Tuesday, December 12 the rating was downgraded by UBS to “Hold”. On Thursday, March 8 the rating was maintained by Credit Suisse with “Outperform”. On Thursday, February 8 the firm has “Buy” rating given by RBC Capital Markets. On Thursday, January 25 the rating was maintained by Barclays Capital with “Overweight”. On Monday, April 30 the stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Buy” rating by Cantor Fitzgerald.

More recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were posted by Seekingalpha.com, Seekingalpha.com and Seekingalpha.com. The first one has “Spark Therapeutics’ (ONCE) CEO Jeff Marrazzo on Q1 2018 Results – Earnings Call Transcript” as a title and was posted on May 08, 2018. The next is “Genomic Medicine: Catch The Gene Therapy Wave” on May 14, 2018. And last was posted on May 08, 2018, called “Spark Therapeutics 2018 Q1 – Results – Earnings Call Slides”.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.